Featured Investments

Watershed moment for pioneering Juva Life as licensed cultivation kicks off

25 Jan 2021 | by: Mark Sheridan


First “Plants In The Ground” Mark The Beginning Of An Exciting Future

Back in 2016, Doug Chloupek’s work in co-founding BAS Research led to it being granted the first ever license for the manufacture and research of medical cannabis in California.

Five years later, the industry visionary is breaking new ground once again with his new company, Juva Life (CSE:JUVA | OTCQB:JUVAF).

But this time, smart investors have the chance to get in early, before the huge potential of this venture is fully realized.

Juva Life (CSE:JUVA | OTCQB:JUVAF) has just been granted a state license for the cultivation of medical and recreational cannabis at its newly renovated, state of the art 30,000 sq ft facility in Stockton, California.

And with plants soon going into the ground, the path to potentially staggering revenues is well and truly clear.

But here’s the thing…

The huge opportunity on the retail side isn’t even the most exciting part of this story.

In fact, it’s not even where most of Juva Life’s (CSE:JUVA | OTCQB:JUVAF) value will come from.

Sure, the new Stockton facility—which has the capacity to produce around 6,000 pounds of high-quality cannabis flower annually—will provide a steady and reliable revenue stream…

But in truth, this is only one part of a much bigger plan.

With Juva Life (CSE:JUVA | OTCQB:JUVAF), Chloupek has taken over a decade of insight and experience to create a company that doesn’t just cultivate cannabis…

It manufactures, distributes, delivers and sells it too.

You’re looking here at a fully vertically integrated cannabis company.

But you’re also looking at a company poised to revolutionize the medical marijuana market…

Put simply, Juva Life (CSE:JUVA | OTCQB:JUVAF) is a cannabis company for the future.


Juva Life (CSE:JUVA | OTCQB:JUVAF) has been set-up in this vertically integrated way for a very specific reason.

Together with a best-of-breed team, Chloupek aims to solve one of the biggest problems faced by the medical cannabis industry.

Which problem?

Evidence. Or rather, the distinct lack of it.

Bottom line is, while many of the historical barriers to medical cannabis use are being broken down and more and more people are starting to seek it out as a real alternative to pharmaceutical drugs…

The fact remains that very little is still known about why cannabis works. Despite knowing that cannabis works, this anecdotal data has not been broken down to reproducible evidence that is customary for doctors, patients and regulators.

Chloupek saw that one of the biggest challenges to improving our understanding of cannabis is in the time it takes to carry out research.

You see, the current standards for pharmaceutical research are put in place largely by worldwide regulatory agencies for good reason – to protect patients and ensure a safety and effective supply of medicines.

But this comes at a cost – time and money.

It is for this reason that many in the cannabis marketplace shy away from doing the hard work required to meet these standards – but not Chloupek and Juva Life (CSE:JUVA | OTCQB:JUVAF).

In fact totally the opposite.

Chloupek has devised a revolutionary new business model.

By coupling translational learning and a vertically integrated cannabis business with pharma discovery and development tools, and availing themselves of the inherent safety and current regulatory structure, Juva Life (CSE:JUVA | OTCQB:JUVAF) generates revenue, learns, and self-funds its proprietary R&D which is the basis of its value creation.

And it does so at a fraction of the cost of its competitors and pharmaceutical counterparts.

You see, the vast majority of cannabis research is done through the Food and Drug Administration (“FDA”). It’s the standard pharmaceutical route, but it costs millions, takes many years, and is often stalled for long periods because of red tape.

In short, all this means Juva Life (CSE:JUVA | OTCQB:JUVAF) can accelerate its understanding of why certain cannabis compounds work to develop important new medicines targeting inflammation and aging.


The precision cannabis opportunity


Juva Life’s (CSE:JUVA | OTCQB:JUVAF) aim is to develop an integrated R&D platform targeting the development of anti-inflammatory evidenced based cannabis products.

Given the need for small molecule anti-inflammatory products the opportunity is significant.

Given that Juva Life (CSE:JUVA | OTCQB:JUVAF) can develop products at a fraction of the time, cost and risk of its competitors, this makes the company an attractive growth opportunity.

The goal is to understand a person’ unique need and match the right product for the right problem.

In drug development this is called personalized or precision medicine.

It is state of the art.

Despite the investment in these tools and infrastructure, the cannabis industry has not availed itself of these best practices – until Juva Life (CSE:JUVA | OTCQB:JUVAF) came along.

The company has figured out how to cherry pick tools from modern learning and technology strategies and combine them with applicable biotechnology practices to accelerate learning.

It can do this at reduced cost and risk – overcoming what is called Eroom’s Law.

When coupled to a vertically integrated manufacturing, retail and commercialization enterprise, Juva Life (CSE:JUVA | OTCQB:JUVAF) reduces its requirements for outside capital, thereby reducing investor and R&D risk.

Bottom line is, by structuring Juva Life (CSE:JUVA | OTCQB:JUVAF) in such a vertically integrated way, Chloupek has created a cannabis company that is truly fit for the future.

It’s a company perfectly positioned to unlock the true potential of medical cannabis at a time when traditional health systems are challenged and new medicines needed.

Demand for natural therapeutics has never been higher.


With cultivation underway…

With research already unlocking new secrets…

And with a team of world-leading scientists and proven experts in the cannabis business leading from the front…

Juva Life (CSE:JUVA | OTCQB:JUVAF) not only offers an attractive proposition for smart investors looking to get in now while the company is still flying under the radar of the mainstream…

It also presents a very attractive proposition for Big Pharma too.

As Chloupek points out:


While the science might be complex, the investment decision is not.

With the medical cannabis market only expected to go one way right now, and with Juva Life (CSE:JUVA | OTCQB:JUVAF) so focused on industry domination…

This is a cannabis play like no other.




This communication is a paid advertisement. ValueTheMarkets is a trading name of Digitonic Ltd, and its owners, directors, officers, employees, affiliates, agents and assigns (collectively the “Publisher”) is often paid by one or more of the profiled companies or a third party to disseminate these types of communications. In this case, the Publisher has been compensated by JUVA LIFE INC. to conduct investor awareness advertising and marketing and has paid the Publisher the equivalent of one hundred sixty-six thousand US dollars to produce and disseminate this and other similar articles and certain related banner advertisements. This compensation should be viewed as a major conflict with the Publisher’s ability to provide unbiased information or opinion.


Readers should beware that third parties, profiled companies, and/or their affiliates may liquidate shares of the profiled companies at any time, including at or near the time you receive this communication, which has the potential to adversely affect share prices. Frequently companies profiled in our articles experience a large increase in share trading volume and share price during the course of investor awareness marketing, which often ends as soon as the investor awareness marketing ceases. The investor awareness marketing may be as brief as one day, after which a large decrease in share trading volume and share price may likely occur.


This communication is not, and should not be construed to be, an offer to sell or a solicitation of an offer to buy any security.


Neither this communication nor the Publisher purport to provide a complete analysis of any company or its financial position.

This communication is based on information generally available to the public and on an interview conducted with the company’s CEO, and does not contain any material, non public information. The information on which it is based is believed to be reliable. Nevertheless, the Publisher does not guarantee the accuracy or completeness of the information. Further, the information in this communication is not updated after publication and may become inaccurate or outdated. No reliance should be placed on the price or statistics information and no responsibility or liability is accepted for any error or inaccuracy. Any statements made should not be taken as an endorsement of analyst views.


The Publisher is not, and does not purport to be, a broker-dealer or registered investment adviser or a financial adviser. The Publisher has no access to non-public information about publicly traded companies. The information provided is general and impersonal, and is not tailored to any particular individual’s financial situation or investment objective(s) and this communication is not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular investor or a personal recommendation to deal or invest in any particular company or product. Any investment should be made only after consulting a professional investment advisor and only after reviewing the financial statements and other pertinent corporate information about the company. Further, readers are advised to read and carefully consider the Risk Factors identified and discussed in the advertised company’s SEC, SEDAR and/or other government filings. Investing in securities, particularly microcap securities, is speculative and carries a high degree of risk. Past performance does not guarantee future results.


This communication contains forward-looking statements, including statements regarding expected continual growth of the featured companies and/or industry. Statements in this communication that look forward in time, which include everything other than historical information, are based on assumptions and estimates by our content providers and involve risks and uncertainties that may affect the profiled company’s actual results of operations. These statements involve known and unknown risks, uncertainties and other important factors that could cause the actual results and performance to differ materially from any future results or performance expressed or implied in the forward-looking statements. These risks, uncertainties and other factors include, among others: the success of the profiled company’s operations; the size and growth of the market for the company’s products and services; the company’s ability to fund its capital requirements in the near term and long term; pricing pressures; changes in business strategy, practices or customer relationships; general worldwide economic and business conditions; currency exchange and interest rate fluctuations; government, statutory, regulatory or administrative initiatives affecting the company’s business.


By reading this communication, you acknowledge that you have read and understand this disclaimer in full, and agree and accept that the Publisher provides no warranty in respect of the communication or the profiled company and accepts no liability whatsoever. You acknowledge and accept this disclaimer and that, to the greatest extent permitted under applicable law, you release and hold harmless the Publisher from any and all liability, damages, injury and adverse consequences arising from your use of this communication. You further agree that you are solely responsible for any financial outcome related to or arising from your investment decisions.


By reading this communication you agree that you have reviewed and fully agree to the Terms of Use found here https://www.valuethemarkets.com/terms-conditions/ and acknowledge that you have reviewed the Disclaimer found here https://www.valuethemarkets.com/disclaimer/. If you do not agree to the Terms of Use, please contact valuethemarkets.com to discontinue receiving future communications.


All trademarks used in this communication are the property of their respective trademark holders. Other than valuethemarkets.com, the Publisher is not affiliated, connected, or associated with, and the communication is not sponsored, approved, or originated by, the trademark holders unless otherwise stated. No claim is made by the Publisher to any rights in any third-party trademarks other than valuethemarkets.com.


valuethemarkets.com and Digitonic Ltd and our affiliates are not responsible for the content or accuracy of this article. The information included in this article is based solely on information provided by the company or companies mentioned above. This article does not provide any financial advice and is not a recommendation to deal in any securities or product. News and research are not recommendations to deal, and investments may fall in value so that you could lose some or all of your investment. Past performance is not an indicator of future performance.

ValueTheMarkets do not hold any position in the stock(s) and/or financial instrument(s) mentioned in the above piece. ValueTheMarkets have been paid to produce this piece by the company or companies mentioned above. Digitonic Ltd, the owner of valuethemarkets.com, has been paid for the production of this piece by the company or companies mentioned above.

Valuethemarkets.com, Digitonic Ltd (and our owners, directors, officers, managers, employees, affiliates, agents and assigns) are not responsible for the content or accuracy of this article. The information included in this article is based solely on information provided by the company or companies mentioned above.

This article does not provide any financial advice and is not a recommendation to deal in any securities or product. Investments may fall in value and an investor may lose some or all of their investment. Past performance is not an indicator of future performance.

    More News & Analysis